Division of Infectious Diseases

World Meningitis Day 2018: #AllMeningitisMatters

It’s World Meningitis Day! #Meningitis affects more than 2.8 million people globally each year.  Meningitis can be a scary disease.  It can be contagious, debilitating, and even deadly.  That’s why it is important to understand what it is, how to recognize it and how to prevent it.

What is meningitis?

The meninges are a set of tissue membranes that line the skull and vertebral column, encasing the brain and spinal cord.  The primary function of the meninges is to protect the central nervous system. If these membranes becomes inflamed for any reason, this condition is called meningitis.

When should we suspect meningitis and how do we diagnose it?

Symptoms of meningitis can progress quickly over hours, or slowly over several days. Individuals with meningitis may complain of fever, headache, nausea, and neck pain or stiffness.  Bright lights or loud sounds may make them feel worse. Without treatment, these symptoms may progress to confusion, stupor, coma or even death.

When these symptoms are identified, medical professionals will obtain a lumbar puncture. This procedure helps to diagnose meningitis by obtaining a sample of fluid from around the spinal cord.  Specific tests should be ordered to look for evidence in the fluid of bacterial, fungal, viral, or even parasitic causes if history suggests.

What causes meningitis?

Viral Meningitis

  • Viral infections by far are the most common cause of meningitis. Enteroviruses are the most common virus identified but the list of viruses causing meningitis is long.
  • Some viral meningitis syndromes can be caused by viruses spread by mosquitoes in warmer weather (such as West Nile Virus)
  • Viral meningitis is typically less severe and most people get better on their own in 7-10 days
  • Some people receive antivirals like acyclovir while awaiting results of spinal fluid testing to rule out herpes simplex virus (HSV) infection
  • Vaccines exist for VZV, mumps, measles and rubella (MMR). These vaccines help prevent systemic disease from these viruses, and subsequently reduce the risk for developing meningitis.

Bacterial Meningitis

  • The most common bacteria responsible for meningitis are: Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae type b (HiB), group B Streptococcus, and Listeria monocytogenes.
  • Some of these organisms, like Streptococcus pneumoniae and Neisseria meningitidis, can be found in the back of the nose and throat of perfectly healthy people. When they get into the wrong place, (i.e. the central nervous system) they start to become a problem.
  • It’s important to note that Meningococcal Meningitis caused by Neisseria meningitidis is not transmitted through casual contact and generally thought of as less contagious than the common cold or flu. However, those with close physical contact or anyone with exposure to an infected person’s saliva via a cough, sneeze or a kiss should be receive antibiotic prophylaxis and contact precautions should be taken
  • There have been outbreaks of bacterial meningitis due to serogroup B meningococcal disease, and meningitis vaccination is recommended for college students
  • If bacterial meningitis is suspected based on spinal fluid testing and presenting symptoms, healthcare professionals will prescribe antibiotics targeting the most likely organisms (empirically) until this information is confirmed.
  • Vaccines exist for Streptococcus pneumoniae, Neisseria meningitidis (may have some protection against gonorrhea as well!!) and Haemophilus influenzae B (HiB)  

Fungal Meningitis

  • Fungal meningitis is rare and usually associated with those with a weakened immune system, like persons living with HIV, cancer patients or transplant recipients.
  • Fungal meningitis cannot be spread between individuals like bacterial meningitis; usually they occur if a person has been exposed to the fungus in the environment and subsequently develops a weakened immune system
  • The types of fungi called endemic fungi can be found in the soil of specific geographic regions. Cryptococcus can be associated with bird droppings. Histoplasma can be associated with bird/bat droppings and is most commonly seen in the Midwest near the Ohio and Mississippi rivers. Blastomyces is also common in soil from the Midwest, and Coccidioides is typically seen in the Southwestern US and South America.
  • recent multistate outbreak of fungal meningitis was associated with use of contaminated steroid epidural or paraspinal joint injections; many fungi were isolated in the outbreak, but the most commonly identified organism was Exserohilum rostratum.

 Parasitic Meningitis

  • Meningitis due to parasites is even more rare than fungal meningitis.
  • Some parasites can cause a type of meningitis called eosinophilic meningitis. These are Angiostrongylus cantonensisBaylisascaris procyonis, and Gnathostoma spinigerum . People can be infected with these parasites by ingesting under-cooked food contaminated with their eggs.
  • Another type of parasitic meningitis is caused by an amoeba called Naegleria fowleri. This causes Primary amebic meningoencephalitis, which is a typically fatal brain infection. People are infected with this organism through contaminated freshwater when it enters the nose forcefully such as when swimming or diving in lakes or rivers, therefore consider plugging your nose as you enter the water if you dive or swim in freshwater.

Non-infectious Meningitis

  • These causes of meningitis include cancer, autoimmune disorders like lupus and drugs including non-steroidal anti-inflammatory medications and antibiotics.
  • Non-infectious Meningitis cannot be spread from person to person.

Treatment and Prevention of Meningitis

  • Think about meningitis if you or your loved one develops any of the symptoms described above.
  • Antibiotics are needed for bacterial meningitis, but do not help with other types of meningitis
  • The most effective way to prevent meningitis is through vaccination when available.
  • If you come into close contact with someone with a known case of bacterial meningitis, your doctor may prescribe you an antibiotic to help prevent you from developing bacterial meningitis too.
  • People who are at most risk for developing meningitis or complications include babies and elderly people, those with weak immune systems and people who do not have a functional spleen. These people should definitely be vaccinated if possible.

Take Away: Meningitis can be scary, so don’t be afraid to ask your local Infectious Diseases specialist for help!  Many of the worst cases can have good recovery if treated early and effectively.

Content courtesy Drs. Randy McCreery MD (IM PGY3, incoming UNMC ID Fellow), and Jasmine R Marcelin MD (UNMC ID Physician)


 

Happy Medical Laboratory Professionals Week!

Providing medical care for a single patient takes a village of health care professionals, and among these, we have some unsung heroes we would like to recognize this week – our Laboratory Professionals!

In Infectious Diseases, we rely heavily on our colleagues working in the lab, particularly in the microbiology lab. They process the cultures and tests to help us identify infecting organisms, determine which antibiotics will kill a certain bacteria, virus or fungus and help push medical care forward through research.  We simply could not do our jobs without all of their hard work, because, just as the hospital never sleeps, neither does the lab.

Thank you for all you do to help us provide excellent care for each and every patient we see!

 

Photos courtesy of Dr. Paul Fey. 


 

WHCyX io bunneiVP pDy

Headed to #ECCMID2018? UNMC ID will be there!

UNMCID is a versatile Infectious Diseases Division, with faculty active in multiple clinical/research pursuits. Some of our faculty are just returning from #SHEA2018 in Portland OR, and others are headed to Madrid Spain to participate in #ECCMID2018 this week from April 21-24. 

If you are going to be in Madrid this week, here’s where to find us at #ECCMID2018. Below is the list of faculty presentations, posters and moderated sessions from our Division.  Find us on Twitter @UNMC_ID ; #UNMCID

Click here for the ECCMID Conference Programme with interactive sessions and schedules. Find out more about #ECCMID2018 and the European Society of Clinical Microbiology and Infectious Diseases.

Poster Presentations

Sunday, April 22 2018 – 12:30-1:30pm

Session name: Bacterial infections in patients with cancer

  • Abstract number: 2926
    Title: Bloodstream infection survey in high-risk oncology patients (BISHOP) with fever and neutropenia (FN): clinical data
    Alison G Freifeld  MD, Andrea J Zimmer MD, Baddley JW; El-Boghdadly Z; Maziarz EK, Montoya JG, Rolston KV, Shoham S; Strasfeld LM; Young JH, Zhang Y, Meza J
  • Abstract number: 4157
    Title: Bloodstream infection survey in high-risk oncology patients (BISHOP) with fever and neutropenia (FN): microbiology data
    Rolston KV, Alison G Freifeld MD,  Andrea J Zimmer MD, Baddley JW; El-Boghdadly Z; Maziarz EK, Montoya JG, Shoham S; Strasfeld LM; Young JH, Zhang Y, Meza J

    Dr. Andrea Zimmer, Assistant Professor of Medicine, Oncology Infectious Diseases Faculty

    Dr. Alison Freifeld, Professor of Medicine, Oncology Infectious Diseases Director

dZ CiMGHexUgCn FPSx

Losing Ground Against Gonorrhea – The Rising Antibiotic Resistance

April is Sexually Transmitted Infection (STI) Awareness month  and there is a critical need to raise awareness toward preventing these infections in all our patients. In the past, most STIs were easily treated with readily available antibiotics, but unfortunately, the story of Gonorrhea has taken a turn down a frightening road.

Gonorrhea is the 2nd most commonly reported transmissible disease and therefore carries recommendations for annual screening among sexually active women < 25 years old and as needed screening for at-risk men and women with unprotected sexual encounters. Testing is simple and done with swabs or urine testing. Sexual partners within the last 60 days are at risk for infection and should be contacted and advised to seek medical care and presumptive treatment. The most recent CDC guidelines recommend treatment with both ceftriaxone and azithromycin, however, these options are starting to run out.

In late March, the UK reported a case of drug-resistant Gonorrhea acquired in southeast Asia that was resistant to, and failed treatment with, first line antibiotics (ceftriaxone and azithromycin) for Gonorrhea. Reports of ceftriaxone resistance have already been reported in several countries. The risk of the eventual emergence of untreatable Gonorrhea is real – and terrifying.

The CDC has been monitoring, and working to prevent, the evolution of drug-resistant Gonorrhea since the 1980’s but it appears we are losing the battle. Resistance has been increasing overtime, with the loss of fluoroquinolones already complicating our current treatment strategies. If cephalosporin and macrolide resistance increase in prevalence, the treatment options are dismal.

So, where do we go from here?

The threat of antibiotic resistance is ever-looming and prevention of the spread of this organism is crucial. Counseling patients on safe sex practices cannot be overemphasized in its importance. Following guidelines for screening, reporting and treating are critical to surveillance and in preventing accidently under-treatment which risks creating increasing resistance patterns. More research is needed on other treatment possible existing treatment options, development of new antibiotics and there may be some hope of future vaccine prevention of gonorrhea.

Wondering how you can help today? Help us raise more awareness of this critical issue – share this information and the above resources with patients, colleagues and on social media.  A healthier future for all demands action now.

 


 

UNMC Goes to Nicaragua on Medical Missions

UNMC medical students, UNMC physical therapy students, Dr. Florescu, and I (Ada, Florescu, a University of Nebraska college student) all started working very early in the morning on March 19th in Managua, Nicaragua. Although it was early in the morning, the heat in Managua was unstoppable and there was no air conditioner anywhere to be found to prevent us all from sweating profusely. From 8 in the morning to 4 in the afternoon, we were dressed head to toe in scrubs and we worked profusely in them.

On the mornings of March 19th and March 20th, UNMC physical therapy students went to a local elderly home where they helped elderly individuals with joint pain. They helped educate these individuals on the importance of exercise and strength in order to improve mobility in tight joints and to relieve pain with time.

The medical students and Dr. Florescu went sent to houses in the community. These houses served as gathering areas for the locals in the community in order for them to receive their medication and treatment.

In the afternoon of March 19th, all groups of students switched locations. The physical students and the medical students joined together at a church where many children and adults waited in line for vaccines. Although the lines appeared endless and the heat blazed throughout the day, all of the patients received the treatments they needed.

In the afternoon of March 20th, all groups joined forces once again in a small office at a local school where lines of students kept forming despite the amount of children that we were seeing. It took a team to tackle that challenge but medical students were administering vaccinations while physical therapy students gave medicine as well as fluoride treatments to all the children.

Although it was a busy spring break for the medical and physical therapy students, no one could say it was anything less than rewarding. Early mornings, sweaty and hot conditions, crying children did not take away any of the value that this trip provided for us as humanitarians.

While working with Los Chavalitos Clinic sponsored by Country-Side Church of Omaha, Nebraska and directed by Dr. Patricia Largaespada, the overall treatments administered in a 3 day period were:

  • Oral anti-polio medication: 20 doses
  • Pentavalent vaccine : 2 doses
  • Pneumococcus vaccine: 3 doses
  • Rotavirus vaccine: 2 doses
  • DPT: 28 doses
  • DT : 176 doses
  • Vitamin A  : 724 doses
  • Fluoride : 715 applications
  • Anti-parasite pills : 980 doses

Patients served:

  • Vaccinations, Vitamin A, Anti-parasites, Fluoride:   989
  • PT services:                                                                       44
  • TOTAL:                                                                               1033

Nothing short of amazing occurs when groups of educated and willing individuals come together. This article reflected the work that was done in Managua, Nicaragua. There were 2 other groups of students and staff that dispersed to Esteli and San Marcos for the same duration of time.

Written by Ada Florescu. 


 

Who’s going to #SHEA2018?

UNMCID is excited to participate in #SHEA2018 this week from April 18-20 in Portland, OR. This is going to be an exciting conference this year, featuring “Education on Innovative Topics Addressing Unanswered Issues in Healthcare Epidemiology, Antibiotic Stewardship, and Post-Acute & Long-Term Care“. 

We want to be sure YOU know where to find us in Portland! Below is the list of faculty presentations, posters and moderated sessions from our Division. Looking forward to seeing you at #SHEA2018! Find us on Twitter @UNMC_ID ; #UNMCID

Click here for the SHEA Spring Conference Brochure, and Schedule-at-a-Glance. Find out more about #SHEA2018 and the Society for Healthcare Epidemiology of America (@SHEA_Epi)

UNMC ID Poster Presentations

Wednesday, April 18, 2018; Poster session Exhibit Hall 12:00 PM – 1:30 PM

  • Presenter: M. Salman Ashraf, MBBS (@M_Salman_Ashraf)
    • Poster Board Number 214: Environmental Cleaning and Disinfection Policies, Protocols and Practices: A Survey of 27 Long-Term Care Facilities
  • Presenter: Jasmine R Marcelin, MD (@DrJRMarcelin)
    • Abstract Number 238: Evaluation of an automatic electronic alert system for re-dosing of antimicrobial surgical site infection prophylaxis

Thursday April 19, 2018; Poster session Exhibit Hall 12:00 PM – 1:30 PM

  • Presenter: Phil Chung, PharmD
    • Poster Board Number 325: Assessment and Implementation of Antimicrobial Stewardship Programs in Long-Term Care Facilities 

UNMC ID Oral Presentations

  • Presenter: Dr. Jasmine Marcelin (@DrJRMarcelin)
    • Friday, April 20, 2018. Session Title: How to Publish What We Do at 10:00 AM – 12:00 PM (Grand Ballroom 2)
    • Presentation: Use of Oral Antibiotic Therapy (OAT) for Definitive Treatment of Uncomplicated Bloodstream Infections (uBSIs)
  • Presenter: Phil Chung, PharmD
    • Friday, April 20, 2018. Session Title: Top Oral Abstracts Session at 2:45 – 4:00 PM (Grand Ballroom 2)
    • Presentation: Assessment and Implementation of Antimicrobial Stewardship Programs in Small and Critical Access Hospitals

UNMC ID Session Moderators

  • Date/Time: Tuesday, April 17 2-6pm.  Pre-conference workshop: Session Title: Spreading Information, Not Infection: Making Infection Prevention and Hospital Epidemiology Digestible for the Public.  
  • Date/Time: Friday, April 20 8:00 – 9:30 am.  Session Title: Pro/Con: Switching it up: Clostridium difficile infection Prevention.  Is Stewardship or Infection Prevention the Key to Reduction?
  • Date/Time: Friday, April 20 8:00 – 9:30 am.  Session Title: LTC: Should I Stay or Should I Go

UNMCID Podium or Lectures

  • Friday April 20, 8:00-9:30 am. Session Title: I’m Here to See the Baby.
    • Presenter: Dr. Kari Simonsen MD (@DrKASimonsen). Seasonal and Age-related visitor restrictions in NICUs: A look at the evidence
  • Wednesday April 18, 2:45 pm – 4:00 pm: Session Title: Electronic Hand Hygiene Monitoring is Needed to Improve Compliance
    • Presenter: Dr. Kari Simonsen MD (@DrKASimonsen)(Pro Position: Electronic Surveillance is Needed to Improve Hand Hygiene Compliance)

EMET Student Profile – Rohan Khazanchi, M1

Tell us about the position you are starting?
I will be joining the HIV Clinic over the next four years as a new HIV Enhanced Medical Education Track (EMET) student. Being in a longitudinal program like this means I will be returning to the HIV clinic throughout my medical training to learn about management of patients with HIV and work on an independent research project. I’m interested in health disparities and hope to conduct a public health study examining differences in the outcomes of our patients based on zip code, race/ethnicity, gender, socioeconomic status, and other social factors.

Background:
I was born in Cincinnati, OH, but grew up here in Omaha and graduated from Millard North High School in 2013. For the last four years, I attended Washington University in St. Louis where I studied Biology (Neuroscience concentration) with minors in Music and Psychological & Brain Sciences. I was involved in a variety of activities at WashU, but my experiences conducting neurobiology research and leading a songwriting program for children who had recently lost close members of their family particularly motivated me to pursue a medical career. I’m excited to be back in Omaha and studying at the College of Medicine for the next four years.

Why UNMC?
I am thrilled to be at an academic medical center that is both a leader in medical education and research. Both my parents are educators, which has contributed to my own interest in academics and medical education. In addition, conducting research has been integral to my development as a physician-in-training. Being at UNMC gives me ample opportunity to continue exploring these interests alongside my medical training.

Why did you choose to apply to the HIV EMET?
With our class being the first to enter a new curriculum, we were fortunate to be taught about HIV during our first months of medical school. I loved hearing from both patients and providers about the unique relationships formed between physicians and their patients with HIV. It is amazing to see how proper treatment can drastically improve quality of life for patients with HIV. In addition, I was drawn to the HIV clinic because of the large number of underserved patients they treat. I hope to continue combating social justice issues and working with underserved patient populations throughout my career.

Something interesting about me not related to medicine:
In college, I was fortunate to be part of an a cappella group (Mosaic Whispers) that ended up advancing to the finals of an international competition (ICCA — the same as Pitch Perfect!), and we performed on a Broadway stage in New York during the finals round. I think it would be fair to say I definitely peaked early…

We wish Rohan the best of luck over the next several years during his journey with us as part of the HIV EMET! More information about the EMET program can be found here.

New Faculty Spotlight – James Lawler, MD, MPH, FIDSA

Dr. Lawler recently joined UNMC and the ID Division serving as the Director of Clinical and Biodefense Research within the
National Strategic Research Institute and Director of International Programs and Innovation with Global Center for Health Security

On a more personal note, we asked Dr. Lawler a few questions: Why did you choose to come to UNMC? What excites you about Infectious Diseases? And we asked him to tell us something unrelated to medicine we may not know about him.

Here are his answers –

WHY UNMC: The people is what really attracted me to UNMC. There is an incredible sense of purpose and teamwork that is pervasive.

ID EXCITEMENT: I love the intellectual challenges of clinical ID emerging infectious disease research.

UNRELATED TO MEDICINE: I am a big college basketball fan.

Thank you Dr. Lawler! We are thrilled to welcome you and work with you going forward.

Learn more about the UNMC ID Division Faculty including Dr. Lawler here.

 


 

Faculty Research Presentation: Bacterial Iron Metabolism and Novel Antimicrobial Strategies

Every month, we have a faculty member presents their ongoing research. Last month we had the opportunity to learn from Dean Bradley Britigan about novel antimicrobial strategies involving disruption of bacterial iron metabolism.  Microorganisms need iron for growth and metabolism; they need it for enzymes, gene regulation, and development of virulence factors. Most bacterial species requiring iron for metabolism secrete siderophores which are low molecular weight proteins that facilitate iron uptake into the cells.

Trojan Horse

Dr. Britigan shared that both Mycobacterium tuberculosis and Francisella tularensis are intracellular pathogens of macrophages that produce siderophores for iron-mediated pathogenesis. In the age of increasing antimicrobial resistance, Dr. Britigan’s work has been dedicated to investigating whether bacterial iron metabolism can be targeted as a novel antimicrobial approach to therapy. They have found some interesting results using gallium as a “Trojan horse”.

Gallium is a trivalent cation with similar size, binding/affinity and molecular properties as a trivalent iron cation, however unlike iron, it cannot be reduced to a divalent state under physiologic conditions; therefore when gallium is substituted for iron in iron-containing enzymes they cease to function. If they saturate the bacterium’s environment with gallium, they can essentially “trick” it into believing it has iron, when it doesn’t. The ability of gallium to disrupt cancer cell iron metabolism via a similar mechanism of action in humans led to FDA approval of gallium nitrate for the treatment of hypercalcemia in malignancy. Early studies showed that gallium inhibited the growth of M. tuberculosis and F. tularensis in macrophages, and reduced the amount of intracellular iron within these bacteria in a concentration-dependent fashion. The inhibitory effect was found to be reversible when extracellular concentrations of iron were increased. In murine models infected with F. tularensis and M. tuberculosis, the overwhelming majority of mice survived infection when treated with gallium.

Cystic Fibrosis

This concept was then applied to Pseudomonas aeruginosa, with particular interest in the cystic fibrosis patient population due to growing antimicrobial resistance and biofilm production. Dr. Britigan’s team in collaboration with investigators at the University of Washington found that gallium also inhibited growth of P. aeruginosa in the murine models of pseudomonas infection, and most mice survived infection with this organism (unless there was significant iron levels in the environment). Remarkably, gallium also inhibited the formation of P. aeruginosa biofilm, with high concentrations killing bacteria within the interior of the biofilm. The mechanism of action for biofilm inhibition has not been fully determined, but they hypothesized that there may be multiple sites of action of the gallium. This hypothesis was tested in vitro with multiple iron-dependent bacterial enzymes including catalase, superoxide dismutase and ribonucleotide reductase, found to be inhibited by the presence of gallium in growth media.

This work has generated enough interest for clinical trials. In the phase 1 trial, the drug appeared to be well tolerated; the phase 2 trial results have not been released.  Dr. Britigan’s lab is continuing to look at clinical isolates before and after treatment with gallium to evaluate for changes in resistance patterns as a result of this treatment, and studies are still ongoing. If applied to clinical practice, gallium would be given intravenously (FDA approved in this form). It’s half-life in the lung is approximately 48-72hrs, and in serum 24hrs, but is not a good candidate for oral formulation as it stands as it is not well absorbed from the gastrointestinal tract. In the cystic fibrosis population the inhaled formulation would be preferred, but studies of the drug in this form are ongoing.

Future Clinical Applications

The clinical application of gallium in bacterial infections would be complementary to the traditional antimicrobials. Gallium is bacteriostatic, which means it inhibits growth rather than kills bacteria. A theory of bacterial resistance mechanisms in biofilm-producing organisms is that the antibiotic cannot penetrate the biofilm adequately, therefore bacteria on inner layers can become resistant.  Gallium synergy would be useful here, because its inhibitory effects extend to biofilm; it can help to penetrate biofilm, reduce bacterial burden and create an environment where bactericidal antibiotics can work more effectively to kill bacteria. Future directions and questions would be to define the forms of gallium that are most effective against target organisms, and expand to include evaluation of additional resistant organisms (e.g. M. abscessus), identify novel drug delivery options (e.g. nanoparticle aerosol delivery), or viral organisms (HIV/TB co-infections).

Teaching Old Drugs New Tricks

In an age where antimicrobial resistance is inevitable, it is a relief to hear about physician-scientists thinking outside the box when it comes to development of antimicrobial agents. Brand new drug development is important but can take up to 10 years along the continuum of drug idea to testing, to FDA approval, to clinical availability. For many of these resistant infections, we may not have 10 years to wait for this process, and this is where re-purposing “old” drugs can be helpful to bridge the gap.

Content Acknowledgement: Thanks to Dr. Bradley Britigan

ID Journal Club Presents…Antimicrobial Stewardship in Immunocompromised Patients with Febrile Neutropenia of Unknown Origin– Focusing on Early De-escalation

Targeted therapy and antimicrobial stewardship in patients with febrile neutropenia is difficult because in the vast majority of cases, an organism is not identified, and patients are known to be high risk for serious infections. Antibiotic de-escalation in patients with neutropenic fever varies, with European guidelines recommending 72hr de-escalation and North American guidelines recommending continuation of broad spectrum therapy until neutrophil engraftment. Dr. Jasmine Marcelin presented a study in ID Journal Club recently that applied an antimicrobial stewardship intervention to this patient population.

Plain Language Summary: The study found that in patients whose blood counts had dropped due to chemotherapy that developed fevers with no identifiable cause, stopping antibiotics 5 days after fevers resolved did not lead to worse outcomes (as compared to continuing antibiotics until blood counts recovered).

Snyder et al; Early Antimicrobial De-escalation and Stewardship in Adult Hematopoietic Stem Cell Transplantation Recipients: Retrospective ReviewOpen Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofx226

The authors of this study sought to provide a middle ground by assessing whether or not patients who were de-escalated after 5 days of therapy (but before engraftment) would have worse outcomes.

This was a single-center retrospective cohort study looking at allogeneic hematopoietic stem cell transplant (HSCT) patients with febrile neutropenia (who had defervesced and were clinically stable) who were de-escalated to neutropenic prophylaxis after 5 days (cohort 1) vs those who were continued on broad-spectrum therapy until engraftment (cohort 2). The study included 120 patients, with 46 in cohort 1 and 74 in cohort 2. The question: if patients are de-escalated after 5 days, are they more likely to have recurrent fever?

In the assessment of recurrent fever, early de-escalation was non-inferior to prolonged broad spectrum antibiotics (15% vs 19%, 90% CI -0.09 to 0.16, p 0.026).  There was no difference in the occurrence or time to re-escalation/re-initiation of broad spectrum antibiotics. Additionally, there were no differences in down-stream effects such as length of stay, ICU admissions, Clostridium difficile infections or in-hospital mortality, and notably, no patients developed bloodstream infection after de-escalation, regardless of recurrent fever. Finally, in the early de-escalation group there were 0.6 days of gram-positive antimicrobial agents per patient compared to 1.7 days per patient in the group that received prolonged broad spectrum antibiotics (p=0.001).

While it certainly does NOT demonstrate that de-escalating after 5 days is better than continuing antibiotics until engraftment, there was no difference in clinical outcomes in patients who were de-escalated early compared with those continued on prolonged antibiotics, with added benefits of reduction of cost and antimicrobial utilization. The authors added that the results of this study have already led to changes in clinical practice at their institution.

The biggest limitation of this study was that it was retrospective: missing data is always a concern. How can we be sure that there were no uncontrolled variables that impacted duration of empiric antimicrobial therapy?   

This article led to great discussion among the group, and fortunately our entire Oncology ID group was in attendance, including Dr. Alison Freifeld, first author of the 2011 IDSA Neutropenic Fever Guidelines and Director of our Oncology Infectious Disease Program here at UNMC ID. Dr. Freifeld commented that “we have been interested in early de-escalation for a while now“, and shared that their group have been even more aggressive than what is described here for early de-escalation. Dr. Andrea Zimmer added that while difficult to quantify, anecdotally there have not been high rates of post-de-escalation febrile illnesses even with aggressive de-escalation.

The Journal Club group also briefly discussed a related study, a recent randomized controlled trial, the “How Long Study” (Aguilar-Guisado, Manuela et al. The Lancet Haematology , Volume 4 , Issue 12 , e573 – e583). In this study, the authors found that in similar high-risk patients with hematologic malignancies or HSCT and febrile neutropenia, empiric therapy could be safely discontinued without neutropenic prophylaxis after 72hrs of being afebrile. Like the study by Synder et al., this RCT noted no difference in rate of recurrent fever, mortality, or other adverse events in the group with antibiotics discontinued compared with continuing empiric antibiotics until neutrophil engraftment.

While it remains to be seen whether early de-escalation or complete discontinuation is the best recommendation, both these studies demonstrate the value of antimicrobial stewardship in the immunocompromised population with febrile neutropenia.  

TNHIHcwQhBfYzfyBAwdoCk VVSh